Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 250.83M P/E - EPS this Y 36.00% Ern Qtrly Grth -
Income -72.89M Forward P/E -4.00 EPS next Y -12.30% 50D Avg Chg -10.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 2.16 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.40 Quick Ratio 21.35 Shares Outstanding 54.91M 52W Low Chg 113.00%
Insider Own 0.49% ROA -17.47% Shares Float 36.14M Beta 0.71
Inst Own 86.09% ROE -31.40% Shares Shorted/Prior 5.05M/2.01M Price 8.95
Gross Margin - Profit Margin - Avg. Volume 256,843 Target Price 24.29
Oper. Margin - Earnings Date May 9 Volume 217,717 Change 3.59%
About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Astria Therapeutics, Inc. News
04/09/24 Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
04/03/24 Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
04/03/24 Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/25/24 Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
03/23/24 Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
03/04/24 Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
02/20/24 Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
02/06/24 Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/30/24 Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc
01/30/24 Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
08:00 AM Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
11/25/23 We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
11/21/23 Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
11/13/23 Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments
11/13/23 Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
11/10/23 Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
11/09/23 Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
11/03/23 Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
10/30/23 Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
10/15/23 Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 60% of the company
ATXS Chatroom

User Image longterminvs Posted - 3 weeks ago

$ATXS https://finance.yahoo.com/news/chief-medical-officer-christopher-morabito-230025213.html

User Image Stock_Titan Posted - 3 weeks ago

$ATXS Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ATXS/astria-therapeutics-announces-inducement-grants-under-nasdaq-listing-67mkpf3jmcp3.html

User Image paavo7303 Posted - 3 weeks ago

$ATXS why it is going down?

User Image StockMilo Posted - 03/31/24

$VINC I’m looking through other biotech SEC filings they all have lots of occasions where they file form 424B5 to allow them to sell stock at opportune moments. Examples include $SLDB https://investors.solidbio.com/static-files/69c03d27-e5b1-4e92-80f3-42621938a852 and $ATXS https://ir.astriatx.com/static-files/9dca2360-8dce-408a-bd59-d72ab9ee542c both of which ended up receiving private placement investments from Perceptive Advisors and other prominent institutional investors. So just because VINC files a 424B5 allowing them to sell up to $50m in common stock doesn’t mean they have to utilize it. It is just an option. Everyone knew they needed to raise capital. So any knee jerk sell off because of the filing is probably an opportunity ahead of some big data being revealed. Just my opinion

User Image Adamo777 Posted - 1 month ago

$ATXS today does not make sense

User Image ChicagoBull0780 Posted - 1 month ago

$ATXS Gap, bleed, pocket, bounce, reverse, retest, repeat....

User Image Lord_Monsoon Posted - 1 month ago

$ATXS proof of concept and … we’re down???

User Image tradingtwenty Posted - 1 month ago

$ATXS has trended 7 times in the past 24 hours (based on 5 minute intervals). Latest press release on Mar 25, 2024 07:30 AM: Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial... Link: https://tradingtwenty.com/news/406732/astria-therapeutics-announces-positive-initial-proof-of-concept-results-from-the-alpha-star-phase-1b2-trial-of-star-0215-for-hae

User Image briefingcom Posted - 1 month ago

Gapping up: $MASI +12.3% $NKTX +11% $ATXS +10.3% $BDSX +7.2% $DJT +4.5%

User Image DonCorleone77 Posted - 1 month ago

$ATXS Astria: 'Positive' initial proof-of-concept results from STAR-0215 for HAE trial Astria Therapeutics announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema HAE patients. Initial results demonstrate a favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, and support both three- Q3M and six-month Q6M dosing regimens. Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026. We are thrilled with these initial results from ALPHA-STAR and believe that STAR-0215 can be a transformative therapy for patients that greatly reduces their disease and treatment burdens," said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics....

User Image Stock_Titan Posted - 1 month ago

$ATXS Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE https://www.stocktitan.net/news/ATXS/astria-therapeutics-announces-positive-initial-proof-of-concept-m7s8byd92wbc.html

User Image Lord_Monsoon Posted - 1 month ago

$ATXS this is quite a ride today….what’s happening?

User Image Bigeyes2 Posted - 1 month ago

$ATXS inverted head and shoulders

User Image ObeCalp Posted - 1 month ago

$ATXS Assuming no big news before tomorrow's open, I'll likely put in a buy order. If it drops after the open, you can blame my purchase.

User Image StockConsultant Posted - 1 month ago

$ATXS Astria Therapeutics stock narrow range breakout watch above 15.53 , see https://stockconsultant.com/?ATXS

User Image TheBigEagle Posted - 1 month ago

$ATXS Right at resistance, let’s see what happens👀

User Image Findingthebull Posted - 1 month ago

$ATXS Trying to add here 13.20’s pre market but doubt will get my low ball fills. Will see if I get lucky.

User Image Stock_Titan Posted - 1 month ago

$ATXS Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ATXS/astria-therapeutics-announces-inducement-grants-under-nasdaq-listing-nseb06rg1ogr.html

User Image MizCo Posted - 1 month ago

$NVO $ATXS $SFIX $EQNR $SLM lol.. what?

User Image Stocksrunner Posted - 1 month ago

🌅 Early Risers Alert! 🚀 Catch the Latest Pre-Dawn Market Moves 📈 $NVO making waves with plans to boost Danish GDP 📉 $ATXS Astria Therapeutics misses Q4 2023 EPS, trade insights with caution. 👗 $SFIX Stitch Fix and Target in focus, earnings report expected today. 💡 $EQNR Equinor ASA announces share buy-back, keep an eye on developments. 💰 $SLM SLM Senior VP Boyles sells 94,078 common shares. Stay informed, trade wisely! 📈

User Image DonCorleone77 Posted - 1 month ago

$ATXS Astria Therapeutics reports Q4 EPS (86c), consensus (78c) "We have strong conviction in the potential for STAR-0215 to be the first-choice preventative therapy for HAE," said Jill C. Milne, Chief Executive Officer at Astria Therapeutics. "Our final data from the Phase 1a trial demonstrate that STAR-0215, in addition to having a trusted modality and proven mechanism, has a favorable safety profile with low risk of injection site pain and has the potential to achieve rapid and durable protection against HAE attacks. We are looking forward to sharing initial proof-of-concept data in HAE patients this quarter and believe they could support dosing as infrequently as every six months. STAR-0310 for atopic dermatitis also remains on track for expected preclinical results later this year and an IND submission by year-end."

User Image Stock_Titan Posted - 1 month ago

$ATXS Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update https://www.stocktitan.net/news/ATXS/astria-therapeutics-reports-fourth-quarter-and-full-year-2023-t10jhn7fhe5y.html

User Image S_Franconi Posted - 1 month ago

$ATXS Thank you ATXS.

User Image satsandstocks Posted - 2 months ago

$ATXS

User Image Findingthebull Posted - 2 months ago

$ATXS Really like this one. Not too much float here. Look at the institutional ownership . Long term hold for me.

User Image TongaGuy Posted - 2 months ago

$ATXS Don't give your shares away! Hold them! The big boys aren't looking to make a few dollars per share. Remember the ultimate goal... https://www.amazon.com/Blood-Money-Billionaires-Biotech-Blockbuster/dp/B0BRYJVS23/ref=sr_1_1?&_encoding=UTF8&tag=spdohgoi-20&linkCode=ur2&linkId=a6655008e34440f79bf8c8d21fada065&camp=1789&creative=9325

User Image Stock_Titan Posted - 2 months ago

$ATXS Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting https://www.stocktitan.net/news/ATXS/astria-therapeutics-to-present-at-upcoming-american-academy-of-vd9torl90afa.html

User Image RallyRaider Posted - 2 months ago

$ATXS STAR0215 only has to be injected every 6 month, no half life issues RA and perceptive increase stake meaningfully. altough bullish im not enthusiastic up here--- just riding a small rest into the horizon

User Image tranq19 Posted - 2 months ago

$ATXS $VSTM ATXS also on a big run...

User Image RallyRaider Posted - 2 months ago

$ATXS would add some if it pulls to 12s, perceptive increasing stake around 12 is great confidence booster.

Analyst Ratings
HC Wainwright & Co. Buy Apr 23, 24
Wedbush Outperform Mar 26, 24
HC Wainwright & Co. Buy Mar 25, 24
Jefferies Buy Mar 25, 24
HC Wainwright & Co. Buy Mar 14, 24
Wedbush Outperform Mar 5, 24
HC Wainwright & Co. Buy Mar 5, 24
Wedbush Outperform Jan 30, 24
Oppenheimer Outperform Nov 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC Director Director Feb 01 Buy 12.09 2,481,350 29,999,522 4,873,721 02/05/24
Morabito Christopher Chief Medical Office.. Chief Medical Officer Jan 26 Sell 11.08 10,000 110,800 01/30/24
Morabito Christopher Chief Medical Office.. Chief Medical Officer Jan 26 Option 3.87 10,000 38,700 9,200 01/30/24
PERCEPTIVE ADVISORS LLC Director Director Dec 19 Buy 11.01 908,265 9,999,998 1,038,309 12/21/22